This damage does not manifest as liver inflammatory damage characterized by significant elevation of ALT or AST, nor as liver failure characterized by the rapid progression of high jaundice and low blood coagulation, but rather as a slow and continuous progression of liver fibrosis and progressive elevation of portal hypertension, which ultimately develop into recurrent complications and cancer due to portal hypertension. The gene discussed is GPT; the disease is liver failure.